Results of a phase IIa trial support further investigation of the selective URAT1 inhibitor verinurad in combination with febuxostat for the treatment of gout.
Treatment with the tumor necrosis factor inhibitor certolizumab pegol during pregnancy is not likely to be associated with teratogenic effects, researchers report.
Results of an observational study suggest that pregnant women with rheumatoid arthritis or axial spondyloarthritis have an elevated risk for pregnancy complications, and disease activity may be a risk factor for preterm delivery.
Patients with glucocorticoid-induced osteoporosis who are treated with denosumab have greater improvements in bone mineral density than those treated with risedronate, phase III trial results suggest.
Phase III trial findings suggest that treatment with the phosphodiesterase 4 inhibitor apremilast is beneficial for patients with psoriatic arthritis who have not received prior treatment with conventional or biologic DMARDs.
Among patients with early rheumatoid arthritis, those who are obese are at increased risk for having worse disease activity, function, and health-related quality of life, according to an analysis of data from two UK cohorts.
The SHARE initiative has developed consensus evidence-based recommendations for the treatment of uveitis associated with juvenile idiopathic arthritis.
Study results from the Osteoarthritis Initiative suggest that diabetes is associated with faster degeneration of knee cartilage among patients with osteoarthritis.
UK researchers have identified characteristics in patients with inflammatory polyarthritis that may make them less likely to respond to oral methotrexate treatment.
The EMA’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the approval of a new infliximab biosimilar for the treatment of various types of arthritis.
The phase III CHABLIS-SC1 trial comparing blisibimod with placebo in patients with systemic lupus erythematosus has not reached its primary endpoint of improvement in the SLE responder index at 1 year, researchers report.
Researchers report that some antirheumatic drugs may limit the humoral response of patients with rheumatoid arthritis to pneumococcal vaccination, but they nonetheless stress that this should not preclude immunization against such preventable diseases.
Commensal bacteria may be involved in triggering systemic lupus erythematosus in genetically predisposed individuals, results of a proof-of-concept study suggest.
Open-label extension results from the RAPID-PsA trial suggest that the benefits of certolizumab pegol are maintained for up to 4 years among patients with psoriatic arthritis.
Rheumatoid arthritis patients who have higher disease activity and those with elevated levels of C-reactive protein are at increased risk for flare following surgery, researchers report.